Market research
NYR.AU Nyrada Inc
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 176M
- P/E ratio
- Not available
- Analyst target
- 0.366
- Dividend yield
- Not available
- Beta
- 0.94
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU0000070195
- Market cap
- 176M
- P/E ratio
- Not available
- Analyst target
- 0.366
- Dividend yield
- Not available
- Beta
- 0.94
About
About Nyrada Inc
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NYR.AU discussion.
5 years, 5 months ago
Nyrada Inc is currently in a long term uptrend where the price is trading 18.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Nyrada Inc gets an overall score of 2/5.